Article
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Bullish
50.0
−100 Bearish
0
+100 Bullish
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
CNBC Top Stories
Published
Mar 27, 2026 · 11:43 am
Article ID
jhgdasi
Original URL
Open source
Sentiment Signal
Bullish
50.0
−100Neutral+100
More Like This